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Abstract 12 
Recent years have seen a massive expansion in our understanding of how we interact with our 13 
microbial colonists.  The development of new, rapid sequencing techniques such as pyrosequencing 14 
and other next-generation sequencing systems have enabled us to begin to characterize the 15 
constituents of our diverse microbial communities, revealing the astonishing genetic richness that is 16 
our microbiome. Despite this, our ignorance of how these communities change over the course of an 17 
HIV infection is profound. Whilst some steps have been made to characterize the HIV microbiome at 18 
selected sites, these reports are still limited and much remains to be done.  It has become apparent, 19 
however, that host-microbiota interactions are perturbed during HIV infections, with microbial 20 
translocation of potential pathogens linked to a variety of different HIV complications, including 21 
more rapid progression of disease. The use of probiotics and prebiotics has been investigated as 22 
treatments to alleviate symptoms for a variety of conditions, and is now being proposed for the 23 
treatment of symptoms associated with HIV.  However, this is a new area of investigations and many 24 
questions remain unanswered.  What we know about both of these topics is a drop in the ocean 25 
compared with what we need to know.  In this article, we report on a workshop where these two 26 
major under-investigated research areas were presented, and future directions explored and 27 
discussed. 28 
Workshop Questions: 29 
1.) What are the key characteristics of the oral microbiome in (HIV)-seropositive people?  Are 30 
there differences in microflora related to HIV? 31 
2.) Are probiotics promising agents in the prevention and/or care of HIV ?  32 
Question 1: 33 
What are the key characteristics of the oral microbiome in (HIV)-seropositive people?  Are there 34 
differences in microflora related to HIV? 35 
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Studies into the host microbiome are an ever increasing field of study. A search of PubMed for the 36 
term 'microbiome' reveals that between 2000 and 2015, there were over 17,000 publications. The 37 
same search term indicated that in 2010, 1,171 publications were highlighted, whilst in 2014, this 38 
number increased to 4,855, indicating the massive expansion in interest in the field of microbiomics 39 
in recent years.  However, despite this surge in interest, the majority of this work has explored either 40 
healthy individuals or chronic systemic conditions such as obesity, diabetes and inflammatory bowel 41 
diseases.  In contrast, relatively few studies (183) have been carried out investigating the host 42 
microbiome during HIV infection, with the majority of these being more recent (64 publications in 43 
2014). This is despite the well known and documented effects that HIV has on host immunity and 44 
associations with opportunistic infections.  It is, therefore, somewhat surprising that so little effort 45 
has been made in investigating the changes in the microbiota  after infection with HIV-1.  46 
The Human Microbiome 47 
It is now well established that mammalian cells make up a minority of the human body, with over 48 
90% of the cells within or on our bodies being of microbial origin (Turnbaugh et al., 2007, Gill et al., 49 
2006). The collective term coined for this wealth of microbial cells is the microbiota, whilst the sum 50 
of their genomes is referred to as the microbiome (Turnbaugh et al., 2007, Peterson et al., 2009). 51 
The bulk of the microbiota are usually regarded as commensal organisms, and exist in the various 52 
niches of the body with a degree of mutualism.  However, in immunocompromised individuals, these 53 
otherwise non-pathogenic organisms may become opportunistic pathogens, and the term 54 
'Pathobiont' has been coined to cover these organisms (Chow et al., 2011). The richness  that the 55 
microbiome adds to the human genome is only now beginning to be realized. If, as has been 56 
proposed, rather than thinking of humans as a purely mammalian organism with microbial 57 
passengers, we think of ourselves as supraorganisms that encompass both human and microbial 58 
symbionts (Lederberg, 2000), then by far the majority of genes in this system are of microbial origin. 59 
Put in context, the 'mammalian' human has roughly the same number of genes as the D. 60 
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melanogaster fruit fly.  However, when the human microbiome is added to the equation, this 61 
similarity is rapidly lost, as fruit flies, like many lower organisms, do not possess the complex 62 
microbiome possessed by humans (Gill et al., 2006, Turnbaugh et al., 2007). Thus, to gain a full 63 
understanding of the human genome, we must also characterize the human microbiome. 64 
Recent attention to the human microbiota has been given to the observations of increased microbial 65 
translocation post HIV infection. These findings have identified an increase in the translocation of 66 
microbes and/or microbial products across epithelial surfaces, without an overt bacteraemia, 67 
occurring after damage to these surfaces. This suggests that deficiencies or defects in the immune 68 
component of mucosal surfaces, along with damage to the local environment, may affect systemic 69 
immunity during the chronic phase of an HIV infection, as surface microbes and microbial products 70 
translocate across these surfaces (Brenchley et al., 2006, Kanwar et al., 2010).Thus, given the 71 
interactions between the microbiota and the host along with its immune system, it is imperative that 72 
we gain a better understanding of how we interact with our microbiota in health and disease. 73 
The human oral microbiome and HIV 74 
A variety of oral manifestations have been associated with HIV infections and have been reviewed 75 
elsewhere (Medel & Hamao-Sakamoto, 2014). In general, the decrease in CD4 cell counts associated 76 
with HIV infection have been strongly linked with the presence of an increase in oral lesions (Hamza 77 
et al., 2006, Greenspan et al., 2004, Greenspan et al., 2001). The advent of successful treatment 78 
therapies for HIV - HAART (Highly Active Antiretroviral Therapy), appears to have had unexpected 79 
effects on oral infections and disease. Treatment of HIV seropositive patients with HAART has led to 80 
an increase in the incidence of human papilloma virus (HPV)-associated oral lesions and recurrent 81 
oral ulceration (Hamza et al., 2006, Ceballos-Salobrena et al., 2000), while the incidence of oral 82 
candidiasis and HIV-associated periodontal diseases have shown a decrease (Hamza et al., 2006, 83 
Greenspan et al., 2001, Greenspan et al., 2004). Although these changes have been linked to 84 
differences in access to oral health care, demographic and social factors and mode of HIV 85 
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transmission, other studies have also linked these changes to co-infection types, disease stages, 86 
immune reconstitution and composition of the oral microbiome - all aspects that will be affected by 87 
the local microbiota. It is therefore evident that the oral microbiota and its associated microbiome 88 
may change significantly as an HIV infection progresses. 89 
A current clinical study has begun to characterize the microbiome in HIV infected individuals (Saxena 90 
et al., 2012, Li et al., 2014, Phelan et al., 2014). This study (Crosstalk among oral and gastrointestinal 91 
soluble innate factors, HIV and  microbes: Grant U19 DE018385; www.nyu.edu/projects/crosstalk/) 92 
set out to examine a population of HIV-infected, antiretroviral-naïve subjects.  The study has 93 
sampled the entire tract from mouth to anus, monitoring changes in proteome, microbiome and 94 
innate immune system, and preliminary results have yielded some interesting findings, relating to 95 
the microbiome during the course of an HIV infection event.  Firstly, using 16S rDNA fingerprint 96 
profiling, the preliminary results indicate differences in profile between the healthy, uninfected 97 
group and the HIV-infected, antiretroviral-naïve group, with the infected group showing a greater 98 
microbial diversity as compared to the uninfected control group.  This supports the hypothesis that 99 
HIV infection significantly changes the host microbiota, altering total microbial colonization and 100 
overall composition of the microbiota in the oral cavity. Using standard cultivation techniques to 101 
quantitatively and qualitatively evaluate the colonisation by several bacterial species, including S. 102 
mutans, S. Sobrinus and total Lactobacillus species, the preliminary results also indicate in increase 103 
in Lactobacillus and S. mutans in HIV-infected individuals as compared to the uninfected group.  Also 104 
increased are the levels of the fungal Candida species, confirming that these normal constituents of 105 
a healthy microbiota show changes in their levels post-HIV infection. Confirmation has also been 106 
obtained using real-time PCR utilizing species-specific primers that there are changes in some of the 107 
primary pathogens associated with periodontitis.  Analyzing the data using cluster analysis at the 108 
genus level indicated a unique microbiome in both groups, as HIV-infected and -uninfected 109 
individuals clustered separately. Taken together, these preliminary data indicate that on HIV 110 
infection there are significant shifts in the host microbiota that may explain some of the oral cavity 111 
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changes seen in HIV-infected individuals, such as increased Candida infections and increased 112 
periodontitis.  113 
Given the changes in oral infection wrought by HAART treatment of HIV-infected individuals (e.g. 114 
decreases in the levels of periodontal disease and oral candidiasis), it is interesting to speculate what 115 
the effects of this treatment are on the oral microbiota changes observed in HIV infection.  To this 116 
end, this study has now looked at HIV-infected patients before and six months following HAART 117 
therapy compared with healthy, uninfected individuals (Li et al., 2014). Using the same three 118 
methodologies (16s rDNA fingerprinting, cultivation and pyrosequencing), this study demonstrated 119 
differences in all three groups, indicating that HAART therapy also has an effect on the oral 120 
microbiota. As with the preliminary data, HIV-positive subjects had higher levels of total cultivable 121 
microbes, including oral Streptococci, Lactobacilli, S. mutans and Candida spp in saliva than did HIV-122 
negative subjects. Further, these levels correlate with the CD4 T cell counts in these groups. A 123 
comparison of the 16S rDNA profiles indicated clear differences between the three different groups, 124 
with some genera (Capnocytophaga, Slackia, Porphyromonas, Kingella, Peptostreptococcaceae, 125 
Lactobacillus, and Atopobium) only detected in the HIV uninfected group.  Interestingly, prevalence 126 
levels of the genera Fusobacterium, Campylobacter, Prevotella, Capnocytophaga, Selenomonas, 127 
Actinomyces, Granulicatella, and Atopobium increased again once an HIV infected patient had been 128 
receiving HAART. In contrast, prevalence of Aggregatibacter showed a significant decrease post 129 
HAART therapy. Taken together, these findings indicate that not only the infection by HIV, but also 130 
the subsequent treatment (HAART) can have a significant impact on the oral microbiota, affecting 131 
microbial colonization and composition. It is important to note that the rebound in microbiota seen 132 
for bacteria  may not occur for the mycobiome (The fungal microbiome). A recent study comparing 133 
HIV-infected patients receiving HAART, compared with healthy controls indicated much the same 134 
findings as Li et al for the bacteriome, with few differences between the healthy and HAART-HIV 135 
groups (Mukherjee et al., 2014).  Combined with the results of the study by Li et al (Li et al., 2014), 136 
these data suggest that the oral bacteriome rebounds once HAART therapy starts. In contrast, 137 
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Mukherjee et al identified significant differences in the mycobiome between the healthy and 138 
HAART-HIV groups.  In particular, they identified that Pichia prevalence was reduced, whilst 139 
prevalence of Candida, Aspergillus and Cryptococcus increased and, in doing so, identified a specific 140 
interaction between Pichia and these three pathogenic fungi.  However, whist they have observed 141 
these effects, given that they have no data on the mycobiome in HIV-infected HAART-naive 142 
individuals, it is not clear if there is any reversion to the normal mycobiome in these patients, or if 143 
these individuals have a third, completely different mycobiome. In summary, whilst HIV infection 144 
clearly affects the oral microbiome, the effects on the oral bacteriome can be partially reversed by 145 
HAART therapy, although any reversal effects on the mycobiome remain to be defined. 146 
 147 
Question 2: 148 
Are probiotics promising agents in the prevention and/or care of HIV ?  149 
As we have seen above, there is a growing body of evidence indicating the important role microbiota 150 
plays in our health.  This has been manipulated over the years without our knowing it by the use of 151 
probiotics.  A probiotic is a microbe that is believed to provide health benefits when ingested.  152 
Currently, the term is used to denote microbes that when consumed are associated with beneficial 153 
attributes to the host. The idea of probiotics is usually ascribed to Élie Metchnikoff who, in 1907, 154 
proposed that 'useful' microbes could be used to replace 'harmful' microbes in the gut and this 155 
process could be encouraged through the consumption of specific foods (Metchnikoff & Mitchell, 156 
1907). Probiotics are now a global market, and claims for their benefits include decreasing the levels 157 
of harmful gut pathobionts, reducing gastro-intestinal discomfort, boosting the immune system, 158 
decreasing host pathogens, maintaining a 'healthy' microbiota during/post antibiotic treatment, 159 
along with a host of other, more esoteric benefits. The recent expansion in the sale and use of 160 
probiotics has resulted in an increase in the standards required to scientifically substantiate the 161 
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claimed beneficial effects of these agents (Rijkers et al., 2011), and to date, no conclusive studies 162 
have been published that reveal a cause-effect relationship, whilst their clinical efficacy remains to 163 
be conclusively proven. 164 
As with microbiome research, this is a field in which there has been a recent surge in activity. A 165 
PubMed search using the search term 'probiotic' reveals that between 2000 and the end of 2014, 166 
13,302 papers were published.  However, the majority of this work has been done over the last five 167 
years.  In 2000, only 212 papers were covered by the search term 'probiotic'.  In contrast, in 2010, 168 
this number had surged to 1,239, and by 2014, the number was 1,961,  indicating this is a healthy 169 
field that is ever expanding.  Given the products that arise from this research and the companies 170 
that can retail them, such as food producers, there is also a significant amount of corporate research 171 
in this area that is driving investigations in several different fields of endeavor. However, 172 
investigations of the role of probiotics in HIV is an area of lower priority.  A search of Pubmed using 173 
the term 'probiotic' and a disease name indicates that between 2000 and 2014, 1,224 papers were 174 
published investigating Inflammatory Bowel Disease and probiotics, 403 investigated Crohn's disease 175 
and probiotics and 565 were published investigating Irritable Bowel Syndrome and probiotics.  In 176 
contrast, over the same time period, only 94 articles were published investigating probiotics and 177 
HIV, with over half of these published since 2010. 178 
One of the main questions regarding the use of probiotics and HIV relates to the effects of probiotics 179 
on the host, given the increased prevalence of microbial translocation in HIV-infected individuals, 180 
and the effect of antiretroviral therapy (ART) on probiotics. The discovery that microbial 181 
translocation across mucosal surfaces can lead to increased inflammation and systemic immunity 182 
(Brenchley et al., 2006) indicated the importance that the microbiota can play in HIV infections. 183 
Systemic immunity activation, such as that induced by microbial translocation is associated with  a 184 
range of non-infectious co-morbidities, all of which  can result in a more rapid progression of the 185 
disease (Sandler et al., 2011, Ancuta et al., 2008). However, although systemic immune activation is 186 
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regarded as playing a role in maintaining the viral reservoir and speeding disease progression to AIDS 187 
(Chomont et al., 2009, Hazenberg et al., 2003) there is contradictory evidence that despite adding to 188 
a microbial load that can be translocated, probiotics may proffer a beneficial effect to HIV-infected 189 
patients (Yang et al., 2014, Cunningham-Rundles et al., 2011) by redressing the balance of 190 
commensals, pathobionts and pathogens resident at a mucosal surface, as well as inducing 191 
improvements in epithelial barrier function.  Thus, there is some debate about whether probiotics 192 
are harmful or beneficial for HIV-infected individuals. 193 
Probiotics have a largely ignored benefit in combating the microbiota changes that occur during 194 
microbial translocation in the course of an HIV infection. However, several recent studies have 195 
provided evidence to support a potential therapeutic role for these microbes - in particular VSL#3 ( a 196 
combination of strains of Bifidobacteria, Lactobacilli and S. thermophila) and Lactobacillus 197 
rhamnosus that have been shown to have health benefits (Barclay, 1999, Corl et al., 2007), with 198 
VSL#3 in particular showing improvements in Inflammatory bowel disease (IBD) (Bibiloni et al., 2005) 199 
by improving barrier function of the GI tract (Sood et al., 2009). Likewise, L. Rhamnosus has been 200 
shown to similarly improve IBD patient prognosis (Gupta et al., 2000). Given the ability of these 201 
organisms to improve disease in IBD patients, it is therefore unsurprising and logical that L. 202 
Rhamnosus has been found to have beneficial effects in HIV-infected individuals (Irvine et al., 2010).  203 
More startling is the finding that this goes hand-in-hand with a marked increase in the levels of 204 
peripheral CD4+ T cells in conventional ART treated HIV-infected patients when given L. Rhamnosus 205 
as a probiotic (Irvine et al., 2010). This effect is not limited to L. Rhamnosus, having recently been 206 
seen with another probiotic (Yang et al., 2014).  207 
Intimately linked with probiotics is the use of non-digestible food ingredients that can be used to 208 
maintain specific microbiota constituents by promoting their growth and activity. These prebiotics, 209 
usually oligosaccharides, directly alter the composition or indirectly affect the microbiota by 210 
assorted effects on the host, such as modulation of gut immunity and changing intestinal transit rate 211 
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among others (Lomax & Calder, 2009, Lohner et al., 2014, Roberfroid et al., 2010). As such, it is 212 
possible that these agents could also impact on the health of an HIV-infected individual in the same 213 
ways as a probiotic.  Indeed, in a pilot study of HAART-naïve HIV-infected patients, a specific 214 
prebiotic restored the gut microbiota, activated CD4+ T cells and reduced microbial products (Gori et 215 
al., 2011).  In summary, whilst little work has been done investigating the potential benefits of pro- 216 
and prebiotics for HIV-infected individuals, the small scale studies currently conducted suggest that 217 
there is potential in this area. 218 
 219 
Future Directions 220 
Whilst a good start has been made in investigating human microbiome during HIV infection, much 221 
work remains to be done.  Given the great diversity seen between individual microbiota, greater 222 
numbers of individuals are needed to increase the sample size and thereby elucidate the core oral, 223 
gut respiratory, vaginal etc microbiota and microbiomes. Importantly, the interaction between the 224 
microbiota and host needs to be investigated. Currently, it is unclear what is causing the changes in 225 
microbiota associated with HIV infection.  Furthermore, the status of the mycobiome has only 226 
recently begun to be investigated, and has revealed significant changes associated with HIV 227 
infection. An important issue that needs to be addressed in future studies is that of sample 228 
collection and patient characteristics.  It is clear that the treatment status of HIV seropositive 229 
patients is critical in understanding the microbiota.  Anti-retroviral therapies, in particular HAART, 230 
clearly have a significant impact on the microbiota.  Likewise, length of infection, underlying co-231 
infections, immune status and diet will all impact on the microbiota.  Thus, sample collection needs 232 
to be standardized and full participant details are needed to make the most effective use of the data 233 
obtained. Attention to these issues would address the following questions: 234 
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 Which comes first? The changes in the mucosa observed during HIV infection, or the 235 
changes in microbiota? 236 
 Are the changes in microbiota due to changes in the immune system, or are they 237 
independent of the immune state of the host? 238 
 What is the effect of the changes in microbiota on the oral, gut and vaginal mucosa? 239 
 What are the changes in the mycobiome and how do they relate to the progression of 240 
disease? 241 
 242 
Despite promising early findings, the potential benefits of probiotics and prebiotics in treating either 243 
HIV infection or its symptoms is currently unclear. The potential that these agents hold for treating 244 
HIV-infected individuals is high.  Given the potential availability and ease with which these agents 245 
can be mass-produced by low tech industries in the food production sector, they hold particular 246 
importance in less wealthy areas.  However, an important note of caution should be sounded. 247 
Although these studies are promising, they are currently few, and the numbers enrolled in them are 248 
low.  So, although the statistical analysis of them is promising, the benefits may not be as apparent 249 
in a larger sample size. Likewise, although a rebound in CD4+ T cells was observed, this could be due 250 
to local inflammation, rather than a general rise in the number of these cells.  Perhaps the biggest 251 
obstacle faced by these agents, however, is the lack of standardization.  The clinical regulatory 252 
bodies of most nations (such as the FDA in the USA) regard these products as food products, 253 
meaning that there is a lack of regulation or licensing of them.  As a result, most research in this area 254 
is carried out by food and nutrition laboratories and companies, rather than medical companies.  255 
Thus, although there is reason for investigation and interest, some important questions need to be 256 
answered. 257 
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 Do probiotics change/alter the microbiota in HIV-infected individuals with and without 258 
standard treatments and therapies? 259 
  How do probiotics change/alter the immunology in HIV-infected individuals with and 260 
without standard treatments and therapies? 261 
 Do probiotics have a clinically beneficial effect in HIV-infected individuals with or without 262 
standard treatments and therapies? 263 
 Is there a reason not to give probiotics to HIV-infected individuals with or without standard 264 
treatments and therapies? 265 
These major areas must be addressed to better understand both the make-up and the role of the 266 
microbiota in preventing/promoting HIV infection, along with treating both the disease and its 267 
associated symptoms. Through better understanding of the microbiota and how it can be 268 
manipulated, we will one day be able to use this knowledge to develop novel prophylactic strategies 269 
to alleviate many of the symptoms of HIV infection.   270 
 271 
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